Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing solutions across the healthcare ecosystem.
As part of the collaboration, the companies will explore co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio plasma focus Dx alongside Illumina's FDA-approved TruSight Oncology Comprehensive for solid tumor profiling.
Both the companies will also continue joint efforts to demonstrate the clinical utility of CGP and promote its adoption.
Currently, ILMN is trading at $122.18, up 1.10 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.